Skip to content

Study · Non-randomized trial · n = 17 · 2014

6 results

Acute metabolic effects of exenatide in patients with type 1 diabetes with and without residual insulin to oral and intravenous glucose challenges.

Ghazi T, Rink L, Sherr JL, Herold KC

Diabetes care12 Aug 2013Cited by 39 (Europe PMC)

PMID23939544 (opens in a new tab)PMCIDPMC3968447 (opens in a new tab)DOI10.2337/dc13-1169 (opens in a new tab)PepBankPUB-23939544
Read at sourcePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In type 1 diabetes, exenatide suppressed meal glucose with or without residual insulin production.

    In plain wordsExenatide lowered meal glucose compared with no exenatide in patients with or without residual insulin production.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseMeal glucose
    Study

    n = 17

    Comparator
    Without exenatide
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    RESULTS During the MMTT, glucose levels were suppressed with exenatide in patients with or without residual insulin production (P = 0.0003).
    1 context sentence
    Summary · context
    RESEARCH DESIGN AND METHODS Seventeen patients with type 1 diabetes, half of whom had residual insulin production, underwent two mixed-meal tolerance tests (MMTTs) and two intravenous glucose tolerance tests (IVGTTs), with and without pretreatment with exenatide.
  2. 02HumanNon-randomized trialMechanism

    In type 1 diabetes, exenatide did not change absolute insulin secretion rate.

    In plain wordsExenatide did not change absolute insulin release compared with no exenatide.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeAbsolute insulin secretion rate
    Study

    n = 17

    Comparator
    Without exenatide
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Exenatide treatment did not change the absolute ISR, but the ISR to glucose levels were increased (P = 0.0078).
    1 context sentence
    Summary · context
    RESEARCH DESIGN AND METHODS Seventeen patients with type 1 diabetes, half of whom had residual insulin production, underwent two mixed-meal tolerance tests (MMTTs) and two intravenous glucose tolerance tests (IVGTTs), with and without pretreatment with exenatide.
  3. 03HumanNon-randomized trialMechanism

    In type 1 diabetes, exenatide increased insulin secretion relative to glucose.

    In plain wordsExenatide increased insulin release relative to glucose compared with no exenatide.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseInsulin secretion relative to glucose
    Study

    n = 17

    Comparator
    Without exenatide
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Exenatide treatment did not change the absolute ISR, but the ISR to glucose levels were increased (P = 0.0078).
    1 context sentence
    Summary · context
    RESEARCH DESIGN AND METHODS Seventeen patients with type 1 diabetes, half of whom had residual insulin production, underwent two mixed-meal tolerance tests (MMTTs) and two intravenous glucose tolerance tests (IVGTTs), with and without pretreatment with exenatide.
  4. 04HumanNon-randomized trialMechanism

    In type 1 diabetes, exenatide delayed gastric emptying.

    In plain wordsExenatide slowed stomach emptying compared with no exenatide.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseGastric emptying
    Study

    n = 17

    Comparator
    Without exenatide
    Outcome group
    Gastrointestinal motility · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Gastric emptying was delayed (P = 0.0017), and glucagon was suppressed (P = 0.0015).
    1 context sentence
    Summary · context
    RESEARCH DESIGN AND METHODS Seventeen patients with type 1 diabetes, half of whom had residual insulin production, underwent two mixed-meal tolerance tests (MMTTs) and two intravenous glucose tolerance tests (IVGTTs), with and without pretreatment with exenatide.
  5. 05HumanNon-randomized trialMechanism

    In type 1 diabetes, exenatide suppressed glucagon.

    In plain wordsExenatide reduced glucagon compared with no exenatide.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseGlucagon
    Study

    n = 17

    Comparator
    Without exenatide
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Gastric emptying was delayed (P = 0.0017), and glucagon was suppressed (P = 0.0015).
    1 context sentence
    Summary · context
    RESEARCH DESIGN AND METHODS Seventeen patients with type 1 diabetes, half of whom had residual insulin production, underwent two mixed-meal tolerance tests (MMTTs) and two intravenous glucose tolerance tests (IVGTTs), with and without pretreatment with exenatide.
  6. 06HumanNon-randomized trialMechanism

    In type 1 diabetes, exenatide did not produce the hormonal or glucose changes during intravenous glucose testing.

    In plain wordsExenatide did not change hormones or glucose during intravenous glucose testing compared with no exenatide.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeHormonal and glucose responses to intravenous glucose
    Study

    n = 17

    Comparator
    Without exenatide
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    None of these hormonal or glucose changes were detected during the IVGTT with exenatide administration.
    1 context sentence
    Summary · context
    RESEARCH DESIGN AND METHODS Seventeen patients with type 1 diabetes, half of whom had residual insulin production, underwent two mixed-meal tolerance tests (MMTTs) and two intravenous glucose tolerance tests (IVGTTs), with and without pretreatment with exenatide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.